Background. Patients undergoing treatment for hematologic malignancy are at a higher risk for developing Clostridium difficile infection (CDI). We sought to determine the epidemiology of toxigenic C. difficile (TCD) carriage and CDI incidence among patients undergoing with newly diagnosed or relapsed acute leukemia.
Background. As rates of pediatric community-associated (CA) Clostridium difficile infection (CDI) increase, additional research is needed to address rates of infection following common antibiotics.
Methods. This study was a retrospective review of the electronic health records of all children with stool specimens sent for C difficile from January first 2012 -December 31 st 2016 at Kaiser Permanente Northern California. Children with clinical symptoms consistent with CDI, confirmatory laboratory testing, no other identified causes of diarrhea, and community associated disease were defined as cases. Using outpatient and ED antibiotic prescription records for children, incidence rates were calculated for subsequent CA CDI for the most commonly prescribed antibiotics.
Results. Of 507 primary CDI cases in our cohort, 327 had any antibiotic use 2012-2015. There were 205 primary CDI cases that were preceded by an antibiotic in the previous 1-365 days. Many of these patients had more than 1 antibiotic in the preceding year.
Of those, rates of CA CDI were uncommon following common antibiotics. (Table) The highest rate of CA CDI followed ceftriaxone, cefdinir, ciprofloxacin and augmentin. The lowest rates were seen following penicillin, doxycycline and azithromycin. Ninetythree percent of the antibiotic prescriptions were in outpatients, 7% in inpatients.
Conclusion.
As rates of CA CDI increase, clinicians should be aware of rates of infection following administration of common antibiotics. The most common antibiotics to cause CA CDI were third-generation cephalosporins (ceftriaxone and cefdinir) and ciprofloxacin.
Disclosures. All authors: No reported disclosures. Background. There is limited data addressing the epidemiology, costs, and outcomes of Clostridium difficile infection (CD) in hospitalized patients in the United States (U.S.). This study aims to estimate the characteristics, outcomes, and economic burden of patients hospitalized for CD in the US.
Increasing Economic Burden of Inpatient
Methods. The Nationwide Inpatient Sample (NIS) database was used to obtain data from 2000-2014. The NIS contains data from over 7 million hospitalizations in the US per year, generalizable to the American population. The NIS was queried for ICD-9 codes for either a primary or secondary diagnosis of CD (008.45). Information for demographic data, length of stay (LOS), mortality, and hospital charges was evaluated.
Results Conclusion. This study demonstrates that the number of hospitalizations for CD has increased by 339% from 2000 to 2014. Inpatient mortality of CD has decreased, likely from earlier recognition and treatment of CD. The direct cost of admissions with CD as primary diagnosis is nearly $4 billion per year. Our findings affirm that CD infection is an epidemic that remains a significant source of morbidity and mortality with substantial hospitalization and cost burden. This data can be used to support a return on investment for intervention strategies to prevent CD transmission and for new therapies. Impact, and Testing Friday, October 6, 2017: 12:30 PM Background. Clinically-confirmed hospital-onset CDI rates declined 15% in VA acute care facilities after implementation of a CDI Prevention Initiative in July 2012. A similar initiative was launched in VA LTCFs in February 2014. The Initiative featured a four-part bundle emphasizing 1) environmental management, 2) hand hygiene, 3) contact precautions for suspected or documented CDI cases, and 4) and institutional culture change where infection control becomes everyone's business. This is a report of subsequent CDI rates in VA LTCFs.
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Declining Rates of Clostridium difficile infections (CDI) in Veterans Affairs
Methods. Multidrug Resistant Organism prevention coordinators at each of the 132 VA reporting sites entered monthly CDI case data from February 2014 to December 2016 into a central database. A clinically-confirmed (CC) LTCF-onset CDI case was defined as a resident with clinical evidence of illness (i.e. diarrhea or histopathologic or colonoscopic evidence of pseudomembranous colitis) and a non-duplicate, non-recurrent positive diagnostic laboratory test collected ≥48h after admission. Quarterly CDI case rate trends were evaluated using negative binomial regression 
